Modulation of the TGFβ1/Smad pathway by the SGLT2 inhibitor dapagliflozin has been shown to attenuate myocardial fibrosis and hypertrophy caused by Ang II administration [34]. The gene discussed is SLC5A2; the disease is Myocardial fibrosis.